HM
RVNC

HealthCor Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

HealthCor Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,590
Closed -$1.74M – 58
2022
Q3 		$1.74M Sell
64,590
-1,353,498
-95% -$27.5M 0.22% 51
2022
Q2 		$19.6M Sell
1,418,088
-5,337
-0.4% -$82.2K 1.97% 20
2022
Q1 		$27.8M Sell
1,423,425
-26,410
-2% -$401K 1.85% 26
2021
Q4 		$23.7M Buy
1,449,835
+1,368,335
+1,679% +$22.8M 1.29% 28
2021
Q3 		$2.27M Buy
+81,500
New +$2.33M 0.1% 59

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthCor Management's RVNC Position: Q4 2022 in Review

HealthCor Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 64,590 shares — an estimated $1.74M sold.

HealthCor Management first reported a position in RVNC in Q3 2021 and held it in 5 quarters. The position peaked at $27.8M in Q1 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • HealthCor Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • HealthCor Management sold 64,590 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $1.74M.
  • HealthCor Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 5 quarters.
  • HealthCor Management's Revance Therapeutics, Inc. position peaked at $27.8M in Q1 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.